Documents | Adalimumab for the treatment of adults with psoriasis | Guidance | NICE

Documents

A list of downloadable documents created during development.

Other information

TA146 Adalimumab ar gyfer soriasis: deall canllawiau NICE (fformat MS Word) 23 March 2009 314 KB

Background information

Review decision - September 2010 information
Appendix A: Decision paper presented to the Institute's Guidance Executive 30 September 2010 105.15 KB
Review proposal - August 2010 information
Appendix A: provisional matrix of stakeholders 23 August 2010 29.28 KB
Appendix B: proposal paper presented to the Institute's Guidance Executive 23 August 2010 284.55 KB
NICE issues guidance on the use of adalimumab for the treatment of psoriasis in adults 06 December 2013 29.3 KB
Review decision - July 2009 information
Review proposal - October 2008 information
Provisional matrix of consultees and commentators 06 December 2013 67 KB
Review decision - December 2008 information
Review decision - December 2008: table of comments 31 December 2008 43.08 KB

Psoriasis - adalimumab: final appraisal determination (FAD)

Psoriasis - adalimumab: final appraisal determination (FAD) information
Psoriasis - adalimumab: final appraisal determination (FAD) 25 April 2008 112.28 KB
Response to consultee, commentator and public comments on the ACD and comments from website consultation 25 April 2008 61.66 KB
Consultee and commentator comments on the ACD
Wyeth Pharmaceuticals 25 April 2008 152.91 KB
Welsh Assembly Government 25 April 2008 13.42 KB
Royal College of Nursing 25 April 2008 20.28 KB
Merck Serono 25 April 2008 282.95 KB
Department of Health 25 April 2008 12.67 KB
British Association of Dermatologists 25 April 2008 13.06 KB
Abbott Laboratories 25 April 2008 24.7 KB

Psoriasis - adlimumab: appraisal consultation

Psoriasis - adlimumab: appraisal consultation information
Psoriasis - adalimumab: appraisal consultation document information
Psoriasis - adalimumab: appraisal consultation - pre-meeting briefing 01 February 2008 178.76 KB
Psoriasis - adalimumab: appraisal consultation - Evidence Review Group report 01 February 2008 447.83 KB
Psoriasis - adalimumab: appraisal consultation - Non-manufacturer submissions
British Association of Dermatologists 01 February 2008 106.92 KB
Psoriasis and Psoriatic Arthritis Alliance 01 February 2008 48.14 KB
Psoriasis Association 01 February 2008 49.4 KB
Royal College of Nursing 01 February 2008 14.76 KB
Royal College of Physicians 01 February 2008 42.83 KB
Welsh Assembly Government 01 February 2008 50.04 KB
Psoriasis - adalimumab: appraisal consultation - Manufacturer submission: Abbott Laboratories Ltd 01 February 2008 1.24 MB
Psoriasis - adalimumab: appraisal consultation - Expert written personal statements
Barker 01 February 2008 16.65 KB
Chandler 01 February 2008 21.95 KB
Griffiths 01 February 2008 17.54 KB
Jobling 01 February 2008 16.48 KB

Psoriasis - adalimumab: Draft scope - pre-referral

Psoriasis - adalimumab: Draft scope - pre-referral 07 September 2007 32.23 KB

Psoriasis - adalimumab: Provisional matrix of consultees and commentators - pre- referral

Psoriasis - adalimumab: Provisional matrix of consultees and commentators - pre- referral 07 September 2007 38.95 KB

Psoriasis - adalimumab: Response to comments on the draft scope

Psoriasis - adalimumab: Response to comments on the draft scope 06 August 2007 126.01 KB